Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
VRCA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $25.20
Previous CloseN/A
Volume115.12K
Average Volume (3M)50.72K
Market Cap
$56.39M
Enterprise Value$73.81M
Total Cash (Recent Filing)$15.40M
Total Debt (Recent Filing)$38.89M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 10, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding9,445,768
10 Day Avg. Volume58,116
30 Day Avg. Volume50,724
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue5.02
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda-1.88
Forecast
1Y Price Target
$20.00Price Target Upside253.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StrategyNon-dilutive financing was secured, providing operational funding through 2025 and into 2026.
Product DemandThe volume of dispensed Ycanth applicator units increased by approximately 33%, indicating strong product demand.
Sales GrowthYcanth sales increased by 33%, slightly surpassing market expectations.
Bears Say
Financial OverhangThere is a need for significantly more sales growth to address the company's financial overhang and funding needs.
Going ConcernA 'going concern' remains despite the recent financing achievements.
Profitability ConcernsThe company is currently not profitable, making a long-term financial solution necessary.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.81 and its highest was $25.20 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $56.39M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 74 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $0.92.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.77.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 9,445,768 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went down -3.372%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (253.36% Upside)
$20.00 (253.36% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.99%
12-Months-Change
Fundamentals
Return on Equity
-1546.58%
Trailing 12-Months
Asset Growth
-24.81%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals (VRCA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of skin diseases. The company primarily targets dermatological conditions, with its lead product candidate, VP-102, designed for the treatment of common skin conditions like warts. Verrica operates in the biopharmaceutical sector, emphasizing the development of topical treatments that leverage its proprietary formulation technologies.
VRCA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in YCANTH sales, strategic partnerships, and improved financial performance, although concerns about future cash flow and reduced R&D expenses were noted.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$20.00
▲(253.36% Upside)
Technical Analysis
PDS Biotechnology
―
Sutro Biopharma
―
PMV Pharmaceuticals
―
Kronos Bio
―
Gain Therapeutics
―
Ownership Overview
44.85% Insiders
3.24% Mutual Funds
0.81% Other Institutional Investors
48.83% Public Companies and
Individual Investors